Friday, October 4, 2013

Drugmakers Question FDA Thinking on New Inspection Powers

The FDA’s interpretation of what constitutes delaying or denying an inspection is far too subjective, and highlights the need for an appeals process for pharma companies flagged as obstructionist, drugmakers say in comments.

No comments:

Post a Comment